CD4 and neoplasm: Antigen presentation can be impaired in malignancy by down regulation of the MHC class I molecules on tumor cells, resulting in an inefficient recognition by CD8+ anti-tumor lytic effectors; and the lack of the MHC class II expression by most human tumors, limiting the simultaneous engagement of CD4+ helper response at the tumor site alongside CD8+ lytic response (88).